1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Physician Views: As race to market intensifies, how expectant are cardiologists for PCSK9 inhibitor class?

Physician Views: As race to market intensifies, how expectant are cardiologists for PCSK9 inhibitor class?

  • August 2014
  • ID: 3509533
  • Format: PDF
  • By Firstword Pharma

Summary






The race to successfully deliver a PCSK9 inhibitor to market for the treatment of hypercholesterolaemia intensified last week with Sanofi and Regeneron Pharmaceuticals unveiling a raft of new late-stage data for their antibody alirocumab.

Furthermore, via novel means (see ViewPoints: But what is an FDA priority review voucher actually worth? BioMarin finally puts a price tag on it), Sanofi and Regeneron appear to have closed the regulatory gap on Amgen, with the US biotech now expected to enjoy first-to-market status for its antibody evolocumab by only a matter of months, according to most estimates.

With Amgen expected to make its initial regulatory filings for evolocumab this quarter and Sanofi/Regeneron anticipating submissions for alirocumab by year end, 2015 is expected to see the PCSK9 class make its long awaited commercial debut – see also FirstWord Lists: Pharma's biggest pipeline drugs.

Regulatory and commercial uncertainties remain, however, with these issues primarily shaped by the demonstrated clinical profiles of both products based on an initial surrogate endpoint (LDL cholesterol reduction) and data from longer-term outcomes studies, which are not due to be published until 2018 onwards.

Although the suggestion that regulatory authorities will not approve products in the class until outcomes data is available have rescinded, debate centres on physician uptake during the first two years of availability based on LDL-C reduction (and the likely trend that usage will be heavily limited to harder to treat hypercholesterolaemia patients).

One potential overhang is data from Merck & Co.'s ongoing IMPROVE-IT study, which is evaluating the clinical benefit of Vytorin across 18000 patients. Should the study not demonstrate a benefit on outcomes (which many commentators and key opinion leaders believe is likely), will this have an impact on the FDA's willingness to approve PCSK9 inhibitors on LDL lowering alone and an impact on physician sentiment towards the PCSK9 class? The 'bull' argument is that LDL-C reduction is better understood than raised HDL levels and that Vytorin is unlikely to demonstrate such a high reduction in LDL-C.

Assuming approval is secured for both leading PCSK9 inhibitors without the requirement for outcomes data, there is limited differentiation between Amgen and Sanofi/Regeneron's products. One opportunity could stem from Amgen's more advanced development of once-monthly dosing (versus once every two weeks for Sanofi/Regeneron), although this requires a longer infusion process – a notable issue given that hypercholesterolaemia patients have typically been treated with oral therapies.









To provide further insight into how the early PCSK9 inhibitor market may evolve we are polling US and EU5-based cardiologists. Specifically we are asking them...


Which dosing regimen (once every two-weeks, which requires 1mL dosing with an auto-injector device, once-every four-weeks dosing, which requires three 1mL injections, or once every four weeks, which required one 10 minute infusion with a pager-sized device) they expect to prove most favourable among patients?
Whether negative data from the ongoing IMPROVE-IT study would have negative implications on their potential usage of the PCSK9 inhibitor class?
To what percentage of statin-intolerant hypercholesterolaemia patients (not at LDL goal) they would anticipate prescribing a PCSK9 inhibitor to two years after launch?
To what percentage of HeFH patients would you anticipate prescribing a PCSK9 inhibitor to two years after launch?
Which dosing regimen (once every two-weeks, which requires 1mL dosing with an auto-injector device, once-every four-weeks dosing, which requires three 1mL injections, or once every four weeks, which required one 10 minute infusion with a pager-sized device) they expect to prove most favourable among patients?





Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Bone Fracture - Pipeline Review, H2 2019

Bone Fracture - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Bone Fracture - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Bone Fracture - Pipeline Review, H2 2019, provides an overview of the Bone Fracture (Musculoskeletal ...

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2019

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2019SummaryPharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2019, provides ...

C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019

C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019

  • $ 3500
  • November 2019

C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019SummaryC-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide ...


ref:plp2014

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on